In a more recent study, molecular tests (EGFR and/or ALK activating mutations, and/or ROS1 rearrangements, and/or PD-L1 expression) were performed in 40% of patients with stage III lung cancer and 60% of those with stage IV lung cancer in the Dolnośląskie voivodeship in 2019–2020 [41]. The gene discussed is EGFR; the disease is lung cancer.